Close Menu

NEW YORK — Cellectricon said on Tuesday that it has signed an agreement to use StressMarq Biosciences' reagents for its neurodegenerative research.

Mölndal, Sweden-based Cellectricon provides drug discovery services, with a focus on chronic pain and neurodegenerative disease. Among its areas of research is the spread of neurodegenerative disease-associated peptides, such as amyloid-beta peptides, tau, and alpha-synuclein, that characterizes Alzheimer's disease and Parkinson's disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.

A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.

Ars Technica reports that a multicellular eukaryotic parasite has lost its mitochondria.

In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.